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In polyglutamine diseases including Huntington’s disease (HD), mutant proteins containing expanded poly-
glutamine stretches form nuclear aggregates in neurons. Although analysis of their disease models
suggested a signiﬁcance of transcriptional dysregulation in these diseases, how it mediates the speciﬁc
neuronal cell dysfunction remains obscure. Here we performed a comprehensive analysis of altered DNA
binding of multiple transcription factors using R6/2 HD model mice brains that express an N-terminal frag-
ment of mutant huntingtin (mutant Nhtt). We found a reduction of DNA binding of Brn-2, a POU domain tran-
scription factor involved in differentiation and function of hypothalamic neurosecretory neurons. We provide
evidence supporting that Brn-2 loses its function through two pathways, its sequestration by mutant Nhtt and
its reduced transcription, leading to reduced expression of hypothalamic neuropeptides. In contrast to Brn-2,
its functionally related protein, Brn-1, was not sequestered by mutant Nhtt but was upregulated in R6/2 brain,
except in hypothalamus. Our data indicate that functional suppression of Brn-2 together with a region-
speciﬁc lack of compensation by Brn-1 mediates hypothalamic cell dysfunction by mutant Nhtt.
INTRODUCTION
Polyglutamine diseases including Huntington’s disease (HD)
are autosomal-dominant, adult-onset neurodegenerative dis-
orders caused by expansion of CAG repeats in certain causa-
tive genes (1–3). In HD, mutant huntingtin containing
expanded polyglutamine forms nuclear aggregates in
neurons. Studies using HD model mice have identiﬁed many
genes whose expression is altered by mutant huntingtin (4–
7). Mutant huntingtin has also been reported to interact and/
or sequester several transcription factors including CREB-
binding protein (CBP) (8,9), TBP (10–12), SP1 (13,14),
TAFII130 (13), p53 (9) and NF-Y (15). These observations
suggest an importance of transcriptional dysregulation in HD
and other polyglutamine diseases (16,17), although how it
mediates neuronal cell dysfunction remains obscure.
In this study, we screened affected transcription factors
using a new strategy in which alterations in their DNA
binding were comprehensively analyzed in brains of a com-
monly used HD mouse model (R6/2) which expresses an N-
terminal (exon1) fragment of mutant huntingtin (mutant
Nhtt). We found the reduction of DNA binding of Brn-2, a
POU domain transcription factor involved in differentiation
and function of hypothalamic neurosecretory neurons. The
reduction of functional Brn-2 was also observed in isolated
hypothalamus of R6/2. Furthermore, in addition to reduced
mRNA expression of vasopressin (VP) and oxytocin (OT) as
previously reported (6), reduced expression of corticotropin
releasing horman (CRH) mRNA was observed without
obvious cell loss. Interestingly, suppression of Brn-2 function
by mutant Nhtt was caused by its sequestration and its reduced
transcription in hypothalamus. In contrast, Brn-1, another
POU domain factor functionally related to Brn-2, was not
sequestered by mutant Nhtt but was upregulated in R6/2
brains, except in hypothalamus, suggesting region-speciﬁc
lack of compensation by Brn-1 in hypothalamus. These data
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hypothalamus-speciﬁc lack of Brn-1 upregulation leads to
hypothalamic cell dysfunction in R6/2 brain. Our ﬁnding pro-
vides a novel mechanism underlying speciﬁc neuronal cell
dysfunction induced by mutant huntingtin.
RESULTS
Identiﬁcation of Brn-2 as a novel mutant Nhtt-affected
factor through functional screening using R6/2 mouse
brain cortex lysates
Our previous observation that a reduction of DNA binding of
NF-Y in cortical lysates of R6/2 HD model mice (15) led us to
try to identify novel mutant Nhtt-affected transcription factors
by monitoring alterations of their DNA binding in the lysates.
For this purpose, we used Protein DNA array technology
(Panomics), which allowed us to measure DNA binding activi-
ties of multiple transcription factors using a 345-probe set con-
taining different binding sequences for transcription factors.
Through the screening, some of the probes showed altered
protein-binding in R6/2 samples (data not shown). We then
performed an electrophoretic mobility shift assay (EMSA)
by using the probes labeled with
32P, and ﬁnally nine probes
were conﬁrmed to show the alterations of the amounts of
protein-DNA complexes in R6/2 cortical lysates. Among
them, probes 1F and 1K contain binding sites for known
affected factors, NF-Y and EGR1, respectively (Supplemen-
tary Material, Fig. S1) (4,15). As for EGR1, its probe
binding and its reduced mRNA expression in R6/2 were con-
ﬁrmed by super-shift assay and RT–PCR analysis, respect-
ively (Supplementary Material, Fig. S1). These data support
that our screening system worked well.
Interestingly, two other probes, 20I (NF-A3) and 2M
(OCT), contain ATGCAAA sequences, which is the binding
site for POU domain transcription factors (Fig. 1A) (18).
Using these probes, we observed three shifted bands by
EMSA (Fig. 1B). The upper, middle and lower bands corre-
spond to the probe complex containing Oct-1 (Pou2f1),
Brn-1 (Pou3f3) and Brn-2 (Pou3f2, N-Oct-3), respectively
(19). Indeed, the middle and lower bands were further
shifted by the addition of antibodies speciﬁc to Brn-1 and
Brn-2, respectively (Fig. 1C, Supplementary Material,
Fig. S2A). Importantly, the Brn-2-probe complex was speciﬁ-
Figure 1. Reduced DNA binding of Brn-2 in R6/2 mouse brain cortex. (A–D) Cortical lysates prepared using high-salt buffer from12-week-old R6/2 (TG; n ¼
3) or control (WT; n ¼ 3) mice were subjected to EMSA using probe 20I (left) or 2M (right). (A) Nucleotide sequences of sense oligonucleotides of the probes.
The binding consensuses of POU domain factors are underlined. (B) Three shifted bands corresponding to the probe-complex containing Oct-1, Brn-1 and Brn-2
are indicated. (C) Super-shift assay using anti-Brn-1, anti-Brn-2 or IgG for probe 20I (left) or 2M (right). (D) Quantiﬁcation of the amount of protein complexes
with probe 20I (left) and 2M (right). Values are means+SD (∗∗P , 0.01). (E) The cortical lysates of R6/2 or control mice were subjected to western blot
analysis using antibodies against Brn-2 (C-2AP), Brn-1 (C-2AP) and b-actin. (F) Quantiﬁcation of the amount of Brn-2, Brn-1 and b-actin. Values are
means+SD (∗P , 0.05).
2100 Human Molecular Genetics, 2010, Vol. 19, No. 11cally reduced in R6/2 samples, whereas probe complexes con-
taining Oct-1 and Brn-1 were not affected (Fig. 1B). Quanti-
ﬁed data showed that the binding of Brn-2 was reduced by
10–20% of control levels in R6/2 cortical lysates (Fig. 1D).
The difference in degree of the reduction between these
probes may be due to the difference in the number of
binding sites (Fig. 1A). These data indicate that Brn-2 is
speciﬁcally affected by mutant Nhtt among the POU domain
factors active in the cortical lysates.
Western blot analysis revealed the reduction of Brn-2
protein in the R6/2 cortical lysates used for Protein DNA
array and EMSA (Fig. 1E and F). Reduced immunoreactivity
of Brn-2 in R6/2 cortex was also observed by immunostaining
with anti-Brn-2 (Supplementary Material, Fig. S3). These data
suggest that reduction of DNA binding of Brn-2 is caused by
reduction of its protein level in the R6/2 cortex lysates.
Brn-2 was sequestered by mutant Nhtt in R6/2 brain
Western blot analysis of cerebrum lysates prepared using SDS
sample buffer also revealed reduction of Brn-2 protein in R6/2
(Fig. 2A and B), whereas the mRNA expression of Brn-2 was
not affected in R6/2 cerebrum (Supplemental Fig. S4A). These
data suggest that protein reduction of Brn-2 is not caused by
its reduced transcription. We then examined whether Brn-2
was sequestered by mutant Nhtt by fractionating homogenate
(lysates) of WT and R6/2 cerebrum as indicated in
Figure 2C. As previously reported (20), smear bands for
mutant Nhtt were detected by anti-polyglutamine antibody in
a 2% SDS pellets of R6/2 but not WT (Fig. 2D and E),
suggesting the formation of SDS-insoluble aggregate of
mutant Nhtt in R6/2 cerebrum. Importantly, Brn-2 was also
observed in the 2% SDS pellet fraction of R6/2 but not WT
in addition to its reduction in 1% sarkosyl supernatant fraction
of R6/2 (Fig. 2D and E), suggesting that Brn-2 forms an
SDS-insoluble complex with mutant Nhtt in R6/2 cerebrum.
On the contrary, Brn-1 was not observed in the 2% pellet frac-
tion (data not shown), supporting the speciﬁc sequestration of
Brn-2 by mutant Nhtt. Taken together, these observations
indicate that mutant Nhtt speciﬁcally sequesters Brn-2 by ren-
dering it insoluble, leading to reduction of functional Brn-2 in
R6/2 brain.
Mutant Nhtt selectively forms SDS-insoluble complex
with Brn-2 in transfected neuro2a cells
How is Brn-2 speciﬁcally sequestered by mutant Nhtt? In con-
trast to the high conservation at C-terminal DNA-binding POU
Figure 2. Reduction of Brn-2 and Arnt2 proteins and their co-fractionation with mutant Nhtt into SDS-insoluble fraction in R6/2 cerebrum. (A) Cerebral lysates
prepared using SDS sample buffer from 12-week-old R6/2 (TG; n ¼ 3) or control mice (WT; n ¼ 3) were subjected to western blot analysis using antibodies
against Brn-2 (C-2AP), Brn-1 (C-2AP), Arnt2 and b-actin. (B) Quantiﬁcation of the amount of Brn-2, Brn-1, Arnt2 and b-actin. Values are means+SD (∗P ,
0.05, ∗∗P , 0.01). (C and D) Cerebrum homogenates (Lysates) of 12-week-old R6/2 (TG) or control (WT) mice were fractionated as shown in (C), and each
fraction was subjected to SDS–PAGE and western blot analysis using antibodies against Brn-2 (C-2AP), Arnt2 and polyglutamine (1C2) (D). (E) 2% SDS pellet
fractions prepared from other R6/2 (TG) or control mice (WT) were subjected to western blot analysis using antibodies against Brn-2 (C-2AP), Arnt2 or poly-
glutamine (1C2).
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Brn-1 and Oct-1 (Supplementary Material, Fig. S5). Interest-
ingly, only Brn-2 contains a polyglutamine stretch (23Q) at
its N-terminal region. In addition, Brn-2 has been shown to
localize to the mutant huntingtin inclusion in transfected
cells (21). We checked interactions of Oct-1, Brn-1 or Brn-2
with mutant Nhtt aggregates by using transfected neuro2a
cells co-expressing Oct-1, Brn-1 or Brn-2 tagged with V5
together with Nhtt containing a pathological stretch of
glutamine (150Q) fused with EGFP and SV40 NLS
(Nhtt150Q-EGFP-NLS). As shown in Figure 3A, Nhtt150Q-
EGFP-NLS formed SDS-insoluble aggregates, which were
detected at the top of the gel by anti-GFP antibody. These
bands were not observed when Nhtt containing a normal
stretch of polyglutamine (Nhtt18Q-EGFP-NLS) was used
(Fig. 3A). Anti-V5 staining showed top bands for Brn-2-V5
in the cells expressing Nhtt150Q-EGFP-NLS, but not in the
cells expressing Nhtt18Q-EGFP-NLS, whereas top bands for
Oct-1-V5 and Brn-1-V5 were not observed in these cells
(Fig. 3A). We also analyzed another POU domain factor,
RPF-1, because it has a polyglutamine stretch (19Q) at the
N-terminal region (Supplementary Material, Fig. S5);
however, a top band was not observed on the gel (Fig. 3A).
This suggests that in addition to the polyglutamine stretch,
its surrounding sequence may be important for the formation
of SDS-insoluble aggregates with mutant Nhtt in neuro2a
cells. We also examined PQBP-1 because it was ﬁrst identiﬁed
as a Brn-2 binding protein and its interaction with soluble
polyglutamine or mutant Ataxin-1, a causative protein for
spinocerebellar ataxia 1, have been reported (22,23).
However, incorporation of PQBP-1-V5 into Nhtt150Q-
EGFP-NLS aggregates was not observed (Fig. 3A), suggesting
that Brn-2 binding to mutant Nhtt aggregates is not through
PQBP-1.
Immunoﬂuorescence analysis of transfected neuro2a cells
showed the preferential localization of Brn-2-V5 to
Nhtt150Q-EGFP-NLS inclusions compared with Oct-1-V5
and Brn-1-V5 (Supplementary Material, Fig. S6A). Quantitat-
ive analysis revealed that most cells showed disappearance of
diffuse Brn-2-V5 in association with its accumulation in
Nhtt150Q-EGFP-NLS inclusions (Supplementary Material,
Fig. S6B). The effective sequestration of Brn-2-V5 with
Figure 3. Brn-2 forms SDS-insoluble complex with mutant Nhtt in neuro2a cells and in vitro.( A) Co-aggregation of Brn-2 with mutant Nhtt in transfected
neuro2a cells. Neuro2a cells were transfected with expression vector for Brn-1, Brn-2, Oct-1, RPF-1, PQBP-1 or LacZ tagged with V5 together with expression
vector for Nhtt18Q-EGFP-NLS (left) or Nhtt150Q-EGFP-NLS (right). After 24 h, cells were subjected to SDS–PAGE and western blot analysis using anti-V5
(upper) or anti-GFP (lower) antibody. Bands for Nhtt18Q-EGFP-NLS are indicated by arrowhead and positions at the top of the gel are indicated by arrows.
Bands for soluble Nhtt150Q-EGFP-NLS were not observed in the gel, possibly due to its efﬁcient insolubilization, but they were detected at the top of the
gel. In the case of Brn-1 and Brn-2, 1/2.5 the amount of plasmid DNA was used to make their expression levels similar to those of other proteins.
(B) Co-aggregation of Brn-2 with mutant Nhtt in vitro. HRV-3C-treated Nhtt18Q, Nhtt62Q or BSA (0.2 mg/ml) was co-incubated with different concentrations
of HRV-3C-treated His-TF-Brn-2 (0, 0.2, 0.5 or 1 mg/ml) at 378C as indicated to the left of panels. After 20 h, the samples were subjected to ﬁlter trap assay and
the aggregated proteins were detected with anti-huntingtin or anti-Brn-2 (C-2AP).
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ation analysis, that is, distinct population of Brn-2-V5 was
detected with Nhtt150Q-EGFP-NLS but not Nhtt18Q-
EGFP-NLS in high-salt buffer-insoluble fraction in association
with reduction of soluble Brn-2-V5 (Supplementary Material,
Fig. S7A–C). In contrast, LacZ-V5 stayed soluble in the cells
expressing either Nhtt18Q/150Q-EGFP-NLS (Supplementary
Material, Fig. S7A–C). Taken together, these data indicate
that among these POU domain factors, only Brn-2 is efﬁ-
ciently sequestered by mutant Nhtt in neuro2a cells.
We also examined the interaction of Brn-2 with soluble Nhtt
using transfected neuro2a cells by immunoprecipitation assay
according to the procedure used for analysis of interactions
between soluble huntingtin and TFIIF subunits (24).
However, coprecipitation of Brn-2 with soluble Nhtt18Q/
62Q proteins was not observed (data not shown), suggesting
that Brn-2 preferentially interacts with the aggregated form
of mutant Nhtt in these cells.
Brn-2 directly incorporated into mutant Nhtt aggregates
in vitro
To test whether Brn-2 directly interacts with mutant Nhtt in
vitro, Brn-2 cDNA was cloned into pCold TF vector;
thereby Brn-2 was expressed as a fusion protein with a His
tag and a trigger factor (TF) under a cold shock promoter in
E. coli, after which His-TF-Brn-2 protein was then puriﬁed
by nickel column (Supplementary Material, Fig. S8A and
C). GST-Nhtt containing 18Q or 62Q was also puriﬁed from
E. coli (Supplementary Material, Fig. S8B and C). After
removal of a GST tag with HRV-3C protease, Nhtt18Q/62Q
was incubated at 378C for 20 h. As shown in Figure 3B,
Nhtt62Q but not 18Q, formed SDS-insoluble aggregates that
were detected by ﬁlter trap assay. Importantly, when
His-TF-Brn-2 treated with HRV-3C was co-incubated with
Nhtt18Q/62Q, Brn-2 also formed SDS-insoluble aggregates
with Nhtt62Q but not Nhtt18Q in a concentration-dependent
manner (Fig. 3B). On the contrary, Brn-2 did not form
SDS-insoluble aggregates if BSA was used as a control
(Fig. 3B), indicating that Brn-2 itself could not form the aggre-
gates and requires mutant Nhtt for its aggregation. Taken
together, these data revealed that Brn-2 was directly incorpor-
ated into mutant Nhtt aggregates in vitro.
Increase in Brn-1 protein in R6/2 brain
Because increased levels and activity of Brn-1 have been
observed in Brn-2 knockout mouse brain (19,25), we
checked the Brn-1 protein level in R6/2 brain lysates.
Western blot analysis revealed increases in Brn-1 in cerebrum
and cortical lysates of R6/2 (Figs 1E and F and 2A and B).
Furthermore, increased immunoreactivity of Brn-1 was
observed in R6/2 cortex by anti-Brn-1 staining (Supplemen-
tary Material, Fig. S3). Because no increase in Brn-1 mRNA
expression in R6/2 brain cerebrum was observed by RT–
PCR (Supplementary Material, Fig. S4B), upregulation of
Brn-1 protein was not caused by its increased transcription
but by other mechanisms such as protein stabilization or
Figure 4. Reduced mRNA expressions of OT, VP and CRH in R6/2 brain hypothalamus. (A) In situ hybridization of coronal sections from 12-week-old R6/2
(TG) or control (WT) mouse brain using antisense probe for VP, OT or CRH. PVN and SON regions are indicated. Scale bar ¼ 400 mm. (B–D) Quantitative
RT–PCR analysis of VP (B), OT (C) or CRH (D) in cerebrum of 4-, 8- or 12-week-old R6/2 (TG; n ¼ 4) or control (WT; n ¼ 4) mice. Values are means+SD
(∗P , 0.05, ∗∗P , 0.01).
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these data support the reduced function of Brn-2 in R6/2
brain, and further suggest that the induction of Brn-1 protein
in R6/2 brain may be a compensation mechanism for the
reduced function of Brn-2.
Reduction of VP, OT and CRH in R6/2 brain
hypothalamus
Studies using Brn-2 homozygous knockout mice revealed the
importance of Brn-2 for the development of two hypothalamic
neurosecretory neurons, magnocellular and parvocellular
neurons (18,19,25). The magnocellular neurons in paraventric-
ular nucleus (PVN) and sporaoptic nucleus (SON) produce
VP) and OT, whereas parvocellular neurons in PVN produce
CRH (Fig. 4A). Although Brn-2 homozygous knockout leads
to complete loss of these neurons (19,25), Brn-2 heterozygous
knockout results in reduced expression of mRNAs for VP
and OT to less than half of normal levels without any morpho-
logical alteration in the hypothalamus (19), indicating that
Brn-2 is also important for expression of these hypothalamic
neuropeptides.
In situ hybridization analysis of R6/2 revealed a distinct
reduction of mRNAs of OT and VP in PVN and SON of hypo-
thalamus, as we previously reported (Fig. 4A) (6). In addition,
clear reduction of CRH mRNA was also observed in PVN
(Fig. 4A). These were further conﬁrmed by RT–PCR analysis
using cerebrum (Fig. 4B–D). Reduced protein expressions of
VP and OT were also observed by immunohystochemical
analysis as reported previously (Supplementary Material,
Fig. S9A) (26). Furthermore, reduction of CRH protein has
been reported (27). It should be noted that hematoxylin stain-
ing revealed no distinct alteration in hypothalamic PVN in R6/
2 (Supplementary Material, Fig. S9B), suggesting no severe
cell loss in these regions of R6/2. These results indicate that
transcription of VP, OT and CRH is reduced in the hypothala-
mus of R6/2 similar to Brn-2 heterozygous knockout
mice, which showed the reduction of those neuropeptide
expressions.
The magnocellular neurons expressing VP and OT project
their axons directly into the posterior lobe of the pituitary
gland. Because loss of posterior lobe has been shown in
Brn-2 homozygous mice (19,25), we examined the morphology
of the pituitary gland in R6/2 mice. Although the posterior lobe
of R6/2 was slightly smaller than that of wild-type (Supplemen-
tary Material, Fig. S10A), the reduction was not as severe as it
is in Brn-2 homozygous mice. In addition, lower but distinct OT
and VP signals were observed in the posterior lobe of R6/2
mouse (Supplementary Material, Fig. S10B; data not shown).
These data also support the idea that the reduced expression
of neuropeptides in R6/2 is not caused by neuronal cell loss
in the hypothalamus.
Figure 5. Reduction of Brn-2 and Arnt2 proteins in R6/2 hypothalamus. (A) Coronal sections prepared from parafﬁn-embedded brain of 12-week-old R6/2 (TG)
or control (WT) mice were stained with antibody against Brn-2 (C-2AP), Brn-1/2 (sc), Brn-1 (C-2AP) or Arnt2. (B) Magniﬁed images of the PVN stained with
antibody against Brn-2 (C-2AP), Brn-1/2 (sc) or Arnt2. Scale bars ¼ 400 mm (A) and 100 mm (B).
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in R6/2 hypothalamus
We next examined whether Brn-2 protein was also reduced in
R6/2 hypothalamus. In control mice, anti-Brn-2 signals were
predominantly observed in PVN and SON neurons in its hypo-
thalamus (Fig. 5A), consistently with previous observations
(19,25). Importantly, these signals were clearly reduced in
12-week-old R6/2 hypothalamus (Fig. 5A). Similar results
were also observed by staining with another antibody,
anti-Brn-1/2 (Fig. 5A), which recognizes both Brn-2 and
Brn-1 (Supplementary Material, Fig. S2A and B). In contrast,
speciﬁc staining was not observed by anti-Brn-1 in PVN and
SON in wild-type mice as previously reported (Fig. 5A)
(25), suggesting that anti-Brn-1/2 stained only Brn-2 in these
regions. Magniﬁed images showed that although the level of
Brn-2 was severely reduced, the number of Brn-2-positive
cells seemed to stay consistent (Fig. 5B), suggesting that the
reduction of Brn-2 is not caused by a loss of Brn-2-positive
cells. Accumulations of Nhtt and ubiquitin, as well as for-
mations of inclusions positive for them were conﬁrmed in
PVN cells of R6/2 mouse (Supplementary Material,
Fig. S11). Thus, Brn-2 protein was reduced in association
with accumulation of mutant Nhtt inclusions in 12-week-old
R6/2 hypothalamus.
Because RT–PCR analysis revealed that the mRNAs of VP,
OT and CRH was not reduced at 4 weeks but started to
decrease at 8 weeks after birth in R6/2 mouse brain
(Fig. 4B–D), we used immunohistochemistry to examine the
Brn-2 protein level in mice of these ages. We found that
Brn-2 together with VP and OT were reduced in hypothalamus
of 8-week-old R6/2 mouse but not that of 4-week-old R6/2
mouse (Supplementary Material, Fig. S12A and B). Thus,
the reduction of Brn-2 protein was correlated with the
reductions of hypothalamic neuropeptides in R6/2 hypothala-
mus.
The reduction of Brn-2 protein in hypothalamus of 8- and
12-week-old R6/2 mice was conﬁrmed by western blot
analysis for isolated hypothalamus lyzed with SDS sample
buffer (Fig. 6A and B and Supplementary Material,
Fig. S12C and D). In contrast, Brn-1 protein levels were not
signiﬁcantly changed (Fig. 6A and B and Supplementary
Material, Fig. S12C and D). Importantly, EMSA using
lysates prepared by high-salt buffer revealed a speciﬁc
reduction in DNA binding of Brn-2 in 12-week-old R6/2
hypothalamus (Fig. 6C and D), in addition to its reduced
protein level (Fig. 6A and B). Thus, functional Brn-2 was
speciﬁcally reduced, together with its reduced protein level
in R6/2 hypothalamus.
Reduction of Brn-2 mRNA in R6/2 hypothalamus
Unexpectedly, in situ hybridization analysis showed reduction
of Brn-2 mRNA in PVN and SON (Fig. 7A). This was con-
ﬁrmed by RT–PCR analysis using isolated hypothalamus;
that is, in addition to reductions of VP and OT, Brn-2
mRNA was also reduced in R6/2 hypothalamus (Fig. 7D).
Almost no VP or OT mRNAs were detected in the remaining
Figure 6. Reduction of DNA binding of Brn-2 in isolated hypothalamus of R6/2 mice. (A) Isolated hypothalamus from 12-week-old R6/2 (TG; n ¼ 5) or control
(WT; n ¼ 5) mice were lysed with SDS sample buffer (upper panels) or high-salt buffer (lower panels), and were subjected to western blot analysis using anti-
bodies against Brn-2 (C-2AP) or Brn-1 (C-2AP). (B) Quantiﬁcation of the amount of Brn-2 and Brn-1. (C) The lysates prepared using high-salt buffer were
subjected to EMSA using probe 20I (left). Super-shift assay using antibodies against Brn-2 (C-2AP) or Brn-1 (C-2AP) (right). (D) Quantiﬁcation of the
amount of protein-probe complexes. Values are means+SEM (∗P , 0.05, ∗∗P , 0.01).
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idea that the hypothalamic PVN and SON are contained in iso-
lated tissues (Fig. 7D). The reduction of Brn-2 mRNA seems
to be speciﬁc to hypothalamus because no alteration of Brn-2
mRNA was observed if we used cerebrum for RT–PCR as
described earlier. In addition, in situ hybridization analysis
showed no distinct reduction of Brn-2 mRNA in R6/2 cortex
(data not shown). Thus, in hypothalamus, reduced transcrip-
tion of Brn-2 may also contribute to the reduction of func-
tional Brn-2 in R6/2 mice.
Reduction of Arnt2 protein and its sequestration
by mutant Nhtt in R6/2 brain
Arnt2, one of the basic helix-loop-helix Per-Arnt-Sim (bHLH-
PAS) family proteins, is another important transcription factor
for differentiation of neurons in PVN and SON (28–30). Impor-
tantly, Arnt2 and its co-factor, Single-minded 1 (Sim1), are
required for expression of Brn-2 during hypothalamic develop-
ment (28–31). Thus, we next examined the possibility of
altered expression of Arnt2 in R6/2 hypothalamus.
We ﬁrst checked the expression of Arnt2 mRNA in hypo-
thalamus. In situ hybridization analysis revealed no clear
reduction of Arnt2 mRNA in PVN and SON of R6/2 hypo-
thalamus (Fig. 7B). Because sequential sections were used
for the detection of Brn-2 and Arnt2, we compared their
mRNA expressions by artiﬁcially labeling their signals.
Merged pictures show a drastic reduction of Brn-2 signals
(blue) compared with Arnt2 signal (red) in R6/2 PVN
(Fig. 7C). RT–PCR analysis using isolated hypothalamus
further supports no distinct reduction of Arnt2 mRNA in R6/
2 mice hypothalamus (Fig. 7D).
In contrast to the mRNA expression analysis, immunohisto-
chemical analysis using anti-Arnt2 antibody revealed distinct
reduction of Arnt2 signals in hypothalamic PVN of R6/2
mice (Fig. 5A and B). The reduction was also observed in cor-
tical regions of R6/2 mice (Supplementary Material, Fig. S3).
Furthermore, western blot analysis showed a reduction of
Arnt2 protein in R6/2 cerebrum (Fig. 2A and B). Because
no alteration of Arnt2 mRNA was also observed in R6/2 cere-
brum by RT–PCR analysis (Supplementary Material,
Fig. S4C), these data indicate that reduction of Arnt2 protein
is not caused by its reduced transcription.
Figure 7. Reduction of mRNA expression of Brn-2 but not Arnt2 in R6/2 hypothalamus. (A and B) Coronal sections from 12-week-old R6/2 (TG) or control
(WT) mouse brain were subjected to in situ hybridization using antisense probe for Brn-2 (A) or Arnt2 (B). Three sections from front to back with 200 mm
intervals were shown. (C) Brn-2 and Arnt2 signals in PVN were artiﬁcially labeled with blue and red, respectively, and merged. Note the drastic reduction
of blue signals (Brn-2) compared with red signals (Arnt2) in R6/2 mouse. (D) Quantitative RT–PCR analysis of Brn-2, Arnt2, VP and OT of isolated hypo-
thalamus from 12-week-old R6/2 (TG; n ¼ 3) or control mice (WT; n ¼ 3). As for VP and OT, RT–PCR data for other cerebral regions of one WT and
one TG after removal of the hypothalamus are also shown. Values are means+SD (∗P , 0.05, ∗∗P , 0.01). Scale bars ¼ 400 mm (A and B) and 100 mm (C).
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C-terminal end, one possibility to explain the reduction of
Arnt2 protein is its sequestration by mutant Nhtt. Indeed,
Arnt2 protein was detected in an SDS-insoluble pellet pre-
pared from R6/2, but not WT, cerebrum (Fig. 2D and E). In
addition, western blot analysis using transfected neuro2a
cells showed the SDS-insolubilization of part of Anrt2-V5 in
the cells expressing Nhtt150Q-EGFP (Fig. 8A). This was con-
ﬁrmed by ﬁlter trap assay, although the amount of trapped
Arnt2-V5 was less than that of Brn-2-V5 (Fig. 8B). Further-
more, partial accumulation of Artn2-V5 to the Nhtt150Q-
EGFP inclusion was also observed by immunoﬂuorescent
microscopy (Supplementary Material, Fig. S6A and B). It
should be noted that similar to Brn-2, Arnt2 did not coprecipi-
tate with soluble Nhtt18Q/62Q proteins from transfected
neuro2a cells (data not shown), suggesting the preferential
interaction of Arnt2 with the aggregated form of mutant
Nhtt in these cells. These data suggest that Arnt2 also
co-aggregates with and is sequestered by mutant Nhtt, which
leads to reduction of soluble Arnt2 in R6/2 brain.
DISCUSSION
In this study, we performed screening of affected transcription
factors in R6/2 HD model mouse brains using a new strategy
and identiﬁed a novel factor, Brn-2, whose DNA binding was
reduced in these brains. Importantly, Brn-2 was sequestered by
mutant Nhtt by co-aggregation. We also found evidence that
mutant Nhtt reduced Brn-2 transcription in hypothalamic
neurons possibly through sequestering Brn-2-upstream regula-
tor, Arnt2. Finally, we showed the reduction of functional
Brn-2 in addition to reduced expressions of VP, OT and
CRH in hypothalamus of R6/2 without obvious cell loss.
These data indicate that Brn-2 loses its function through two
pathways, its sequestration by mutant Nhtt and its reduced
transcription, resulting in the reduced transcriptions of VP,
OT and CRH (Fig. 9). Thus, our screening-based analysis
could identify novel mutant Nhtt target, Brn-2, which mediates
hypothalamic cell dysfunction in HD model mouse brain.
Identiﬁcation of novel affected transcription factors
by mutant Nhtt in vivo
Although previous studies have identiﬁed potential targets of
mutant huntingtin, such as CBP, TBP, SP1, TAFII130 and
p53 (32,33), several in vivo studies did not fully support
their sequestrations and/or suppressions but rather suggested
upregulations of some of these in HD model mouse brain
(15,34–37). Thus, their direct roles for transcriptional dysre-
gulation in HD are still controversial.
Recently, we have performed screening of interacting pro-
teins of mutant Nhtt aggregates puriﬁed from cultured
neuro2a cells and identiﬁed NF-Y transcription factor as a
novel protein sequestered by mutant Nhtt (15). Importantly,
sequestration/suppression of NF-Y leads to reduced HSP70
expression in HD model mouse brain. Thus, our previous
study supported an importance of screening-based approach
for analysis of the transcriptional dysregulation induced by
mutant huntingtin. However, with the exception of CA150, a
known huntingtin aggregate-interacting protein (38), no
other transcription factors were obtained through this system
possibly because of limitation of use of the cultured cell line
as a brain neuronal model (see what follows).
This problem was overcome in this study by using HD
model mouse brain as a material and by performing the
screening using new strategy in which alterations in DNA
binding of transcription factors were comprehensively ana-
lyzed by Protein DNA array. We identiﬁed Brn-2 as a novel
protein affected by mutant Nhtt, in addition to known affected
factors, NF-Y and EGR1. In addition, detailed analysis further
identiﬁed Arnt2 as another protein sequestered by mutant Nhtt
in the model mouse brain. Our study is sharp contrast to the
previous studies identifying the targets described above
because they were found on the basis of their interactions
Figure 8. Arnt2 forms SDS-insoluble aggregates with mutant Nhtt in neuro2a
cells. (A) Neuro2a cells were transfected with expression vector for Arnt
(isoform a or b) or Arnt2 tagged with V5 together with expression vector
for Nhtt18Q-EGFP-NLS or Nhtt150Q-EGFP-NLS. After 24 h, cells were sub-
jected to SDS–PAGE and western blot analysis using antibody against V5
(left) or GFP (right). Bands for Nhtt18Q-EGFP-NLS are indicated by arrow-
head and positions at the top of the gel are indicated by arrows. Bands for
soluble Nhtt150Q-EGFP-NLS were not observed in the gel but detected at
the top of the gel. In the case of Arnt2, 1/2.5 the amount of plasmid DNA
was used to make its expression levels similar to those of other proteins.
(B) Neuro2a cells were transfected with expression vector for Brn-2, Arnt2
or LacZ tagged with V5 together with expression vector for
Nhtt18Q-EGFP-NLS or Nhtt150Q-EGFP-NLS. After 24 h, cells were lysed
with SDS-sample buffer and were subjected to ﬁlter trap assay. The aggre-
gated proteins were detected with anti-V5 or anti-GFP.
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Arnt2 are not observed in neuro2a cells (T.Y., N.N., unpub-
lished data), supporting the signiﬁcance of use of in vivo
system for analysis of the transcriptional dysregulation
induced by mutant huntingtin.
Involvement of differential transcriptional dysregulation
by mutant Nhtt in its tissue/cell-speciﬁc effects
on R6/2 mice
We found the induction of Brn-1 protein expression in cortical
region of R6/2 HD model mice. Importantly, increase in Brn-1
DNA binding has been shown in Brn-2 knockout mice brain
(19). In addition, increased cortical staining of Brn-1 has
been observed in a Brn-2 knockout mouse, although the
authors did not explicitly report this phenomenon (25). Thus,
these observations also support the reduction of functional
Brn-2 in R6/2 mouse brain. Importantly, the induction of
Brn-1 expression was not observed in hypothalamic PVN
and SON, where only Brn-2 is expressed, suggesting that
co-expression of these two proteins is required for Brn-1 upre-
gulation upon Brn-2 dysfunction.
Brn-1 and Brn-2 double-knockout mice show suppressed
cortical development, due to reduced transcription of several
important regulators including p39, a CDK5 regulatory
subunit, during embryogenesis (39,40). It should be noted
that our in situ hybridization analysis revealed no reduction
in cortical p39 expression in 12-week-old R6/2 mouse brain
(Supplementary Material, Fig. S13). In addition, RT–PCR
analysis showed no distinct reduction of p39 in 12-week-old
R6/2 mouse cerebrum (data not shown). These data suggest
that total Brn-1/2 activity is not affected in R6/2 brain.
Although wecouldnotdirectlyobservethelack of compensatory
effect by Brn-1 in hypothalamus by in situ hybridization
analysis because there is no p39 expression in this region of
control mice (Supplementary Material, Fig. S13), our data
strongly support the idea that region-speciﬁc upregulation of
Brn-1 compensates for Brn-2 dysfunction in the cortex but
not in the hypothalamus of R6/2 mice, resulting in hypothala-
mic cell dysfunction in these mice (Fig. 9).
Our data also suggest that the reduction of Brn-2 mRNA is
speciﬁc to hypothalamus in R6/2 mice, whereas the protein
level of its upstream regulator, Arnt2, was decreased in
whole cerebrum including hypothalamus and cortex in these
mice. One possible mechanism could be the limited expres-
sion of Sim1, an Arnt2 functional co-factor. This would
conﬁne the Anrt2 dysfunction-induced suppression of Brn-2
expression to the hypothalamus of R6/2 because Arnt2 homo-
zygous mutation has been reported to lead to suppression of
Brn-2 expression only where Arnt2 co-localizes with Sim1
during hypothalamic development (30). Consistently, in situ
hybridization analysis revealed that Sim1 mRNA signals
were exclusively observed in hypothalamus but not in other
regions, including cortex, in both 12-week-old control and
R6/2 mouse brains (data not shown). Thus, Arnt2 could be
functional for Brn-2 expression only when it forms a protein
complex with Sim1 in hypothalamus, and Arnt2 sequestration
by mutant Nhtt may lead to reduction of the functional Arnt2–
Sim1 complex, resulting in hypothalamus-speciﬁc reduction of
Brn-2 expression in R6/2 brain (Fig. 9).
Interestingly, increased expression and/or transcriptional
activity in HD model mouse brain has been observed for
other transcription factors reported to be affected by mutant
huntingtin. These include increased mRNA expression of
NF-Y components (15), increased protein/mRNA expression
of SP1 (36), increased protein and transcriptional activity of
Figure 9. Hypothetical model. (A) In control mouse brain, Brn-2 is involved in the expression of neuropeptides in hypothalamus, whereas both Brn-2 and Brn-1
are involved in the expression of their target genes including p39 in cortex. Arnt2 regulates Brn-2 expression only in hypothalamus by forming a protein complex
with its hypothalamus-speciﬁc co-factor, Sim1. (B) In R6/2 HD model mouse brain, mutant Nhtt sequesters Brn-2, leading to a reduction of functional Brn-2.
Mutant Nhtt also sequesters Arnt2 to reduce the functional Arnt2-Sim1 complex, which further contributes to the reduction of functional Brn-2 by its reduced
transcription. The suppression of Brn-2 as well as a lack of upregulation of Brn-1 leads to reduced expressions of neuropeptides in hypothalamus. In contrast,
expressions of cortical Brn-1/2 targets including p39 are not affected possibly because of compensation of Brn-2 suppression by upregulated Brn-1.
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transcription (35). It should be noted that p53 has been shown
to be induced in a cell-type-speciﬁc manner; that is, mutant
huntingtin induces p53 expression to suppress HSP70 induc-
tion in cortical neurons, which are highly sensitive to mutant
huntingtin-induced degeneration, but not in cerebellar
granule cells, which are insensitive to it (41). Thus, precise
analysis focused on increased expression/activity of these pro-
teins might lead to identiﬁcation of a novel mechanism under-
lying the region- and cell-type-speciﬁc degeneration observed
in HD.
Dysregulated expression of hypothalamic neuropeptides
in HD model mice and HD patients
Although the expression of CRH was shown to be reduced in
R6/2 mice, CRH downstream factors, pituitary adrenocortico-
tropic hormone (ACTH) and serum corticosterone have been
shown to be increased in R6/2 mice (42). This seems to be
caused by an alternative compensatory mechanism because
expressions of ACTH and corticosterone have been shown
to be not affected in Brn-2 homozygous knockout mice
despite the loss of hypothalamic neurons expressing CRH in
those mice (25). Importantly, increase in ACTH and corticos-
terone has been also reported in HD patients (42,43), which
may contribute some of HD clinical symptoms, such as
impaired glucose metabolism and muscular wasting (44).
Recently,Wood etal.( 26) reported increased thirstand drink-
ing inR6/2, which may berelated toreductionofVP in its hypo-
thalamus. Increased thirst was also observed in HD patients
(clinical stage III), although serum VP was increased in these
patients. One possibility is that hypothalamic neurons in HD
patients up to this stage could increase VP release to maintain
body water balance, as the authors suggested. Because R6/2
mice express a very long glutamine stretch (more than 120Q),
VP could be decreased in advanced clinical HD or juvenile
HD. Expression of a shorter fragment of huntingtin in R6/2
mice may also enhance and/or spread the mutant huntingtin’s
effects. Interestingly, recent studies using human and animal
models have revealed an importance of VP and OT for social
cognition/behavior (45). Further studies will be necessary to
clarify the pathological signiﬁcance of altered transcriptions of
VP, OT and CRH observed in the HD model mice.
In addition to VP, OT and CRH, we have previously
found reduced transcription of other hypothalamic neuropep-
tides including neuropeptide Y, prepro-thyroid-stimulating
hormone (TSH)-releasing hormone and prepro-somatostatin.
Furthermore, recent studies have found several degenerations
in some hypothalamic neurons of HD patients and HD
model mice (44); that is, loss of somatostatin-containing
neurons in the lateral tuberal nucleus in HD patients (46),
and loss of orexin-containing neurons in the lateral hypothala-
mic area of HD model mice and HD patients (47). It should be
noted that the reductions of VP and OT are also observed in
brains of model mice for another polyglutamine disease,
dentatorubral-pallidoluysian atrophy (DRPLA) (48). Further
studies will be needed to deepen our understanding of molecu-
lar mechanisms and pathological signiﬁcances of dysfunction/
degeneration of several hypothalamic neurons induced by
mutant huntingtin or other polyglutamine disease proteins.
Conclusion
In summary, our screening-based approach identiﬁed novel
affected factors by mutant Nhtt, which mediate the region-
speciﬁc cellular dysfunction in HD model mice. Further
studies focused on selective and differential transcriptional
alterations may identify a novel mechanism underlying the
cell/tissue-speciﬁc dysfunction observed in HD and other
polyglutamine diseases.
MATERIALS AND METHODS
Mice
The mouse experiments were approved by the animal exper-
iment committee of the RIKEN Brain Science Institute.
Mice were maintained and bred in accordance with RIKEN
guidelines. Heterozygous htt exon 1 transgenic male mice of
the R6/2 strain were obtained from Jackson Laboratory (Bar
Harbor, ME, USA). In this paper, only males of R6/2 (over
120 CAG repeats) and age-matched control mice were used
for experiments. For most of the histological analysis includ-
ing hematoxylin staining, immunohistochemistry and in situ
hybridization, we used R6/2 and control littermates. For bio-
chemical analysis including Protein DNA array, EMSA,
brain fractionation and RT–PCR, we used several littermates
to obtain enough R6/2 and control samples.
Antibodies
Polyclonal antibodies, Brn-2 (C-2AP) and Brn-1 (C-2AP),
were generated against the C-terminal 14 amino acid of
mouse Brn-2 or Brn-1, respectively. Each antibody was puri-
ﬁed by respective antigen peptide conjugated to SulfoLink
Coupling Gel (PIERCE Biotechnology, Rockford, IL, USA).
Anti-htt (EM48; MAB5374), anti-polyglutamine (1C2;
MAB1574), anti-VP (AB1565), anti-OT (AB911) and anti-
ubiquitin (MAB1510) were from Chemicon International
(Temecula, CA, USA); anti-Brn-2 (sc-6029; referred to as
anti-Brn-1/2 (sc) in this paper because it recognizes both
Brn-1 and Brn-2), anti-EGR1 (sc-110) and anti-Arnt2
(sc-5581) were from Santa Cruz Biotechnology Inc.; anti-V5
(R960-25) was from Invitrogen; anti-b-actin (A5441) was
from Sigma-Aldrich.
Expression vectors
The mouse cDNAs for Brn-1, Brn-2 and Oct-1 were cloned
from mouse brain cDNA by standard PCR methods. The
mouse cDNAs for Arnt (isoforms a and b), Arnt2, RPF-1
and PQBP-1 were kindly provided as FANTOM3 clones
(49). These cDNAs were subcloned into a pcDNA3.1/
V5-His or pcDNA-DEST40 vector (Invitrogen) for expression
in mammalian cells. pcDNA3.1-LacZ/V5-His was from Invi-
trogen. cDNAs for N terminal huntingtin (exon 1) containing
a polyglutamine stretch (18Q, 62Q or 150Q) fused with EGFP
and SV40 NLS subcloned into pcDNA3.1 vector (Invitrogen)
were described previously (50). cDNA for Brn-2 was sub-
cloned into pCold TF (Takara) for expression in E. coli.
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Isolated tissues (cortex or hypothalamus) from mouse brains
were homogenized for 10 strokes with lysis buffer containing
20 mM Hepes, pH 7.9, 25% glycerol, 150 mM NaCl, 1.5 mM
MgCl2 and complete protease inhibitor using a glass hom-
ogenizer, after which time NaCl was added to a ﬁnal
concentration of 420 mM. After incubation on ice for 20 min,
the lysates were centrifuged at 800g for 5 min, and further
clariﬁed by centrifugation at 20 000g for 30 min. The super-
natants were used for Protein DNA array and EMSA.
Protein DNA array (Panomics) was performed according to
the manufacturer’s protocol. The array we used here was
Combo Array, which contains 345 spots for probes. Brieﬂy,
the tissue lysates were pre-incubated with a mixture of biotin-
labeled probes containing binding sequences for different tran-
scriptional factors to allow the formation of protein/probe
complexes. After separation of the complex from the free
probes by column ﬁltration, the probes in the complexes
were extracted and hybridized to the array. Then, hybridized
probes were labeled with streptavidin-HRP and detected by
Chemiluminescent regent. EMSA was performed as described
previously (15).
Cell culture, transfection and fractionation
Neuro2a cells were maintained in DMEM supplemented with
10% FBS and penicillin-streptomycin in an atmosphere con-
taining 5% CO2. Transfection was performed by Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s
protocol. For fractionation, frozen cells were suspended with
200 ml of lysis buffer containing 20 mM Hepes, pH 7.9, 25%
glycerol, 150 mM NaCl, 1.5 mM MgCl2 and complete protease
inhibitor, after which NaCl was added to a ﬁnal concentration
of 420 mM. After incubation on ice for 20 min, the lysates
were subjected to ultracentrifugation (TLA55; Beckman
Coulter) at 50 000 rpm for 30 min at 48C, and a supernatant
was saved as a lysis buffer-soluble fraction. The pellet was
washed once with the lysis buffer, and incubated in 100 ml
of formic acid at 378C for 1 h. After being dried up using a
Speed-Vac, 200 ml of lysis buffer was added to the pellet.
The supernatant and pellet fractions were redissolved/soni-
cated and boiled in SDS sample buffer and subjected to
western blot analysis as described previously (51). Chemilu-
minescent signals were obtained and quantiﬁed using
LAS-1000 (Fuji ﬁlm).
Immunoﬂuorescence microscopy
and immunohistochemistry
Transfected neuro2a cells were ﬁxed with 4% paraformalde-
hyde/PBS and stained as described previously (15).
Parafﬁn-embedded brain coronal sections (5 mm thick) were
deparafﬁnized, autoclaved in 10 mM citrate buffer (pH 6.0)
at 1208C for 5 min and stained as described previously (52).
Brain fractionation
Homogenization and fractionation of 12-week-old R6/2 or
control mice cerebrum shown in Fig. 2C were performed as
described previously (20). The lysates or fractions were
boiled in SDS sample buffer and subjected to western blot
analysis as described previously (51). Chemiluminescent
signals were obtained and quantiﬁed using LAS-1000
(Fuji ﬁlm).
RNA preparation, cDNA synthesis and quantitative
real time PCR
Preparations of total RNA, reverse transcription and cDNAs
synthesis from mouse cerebrum were performed as described
previously (52). Primers and TaqMan probes for quantitative
real-time PCR were designed based on Primer Express soft-
ware (Applied Biosystems). Nucleotide sequences are listed
in Supplementary Material, Table SI. The real-time PCR
was performed by TaqMan (VP, OT, Brn-2) or SYBR green
(GAPDH, CRH, Brn-1, Arnt2, EGR1) according to the manu-
facturer’s protocol (Applied Biosystems). All values obtained
were normalized with respect to levels of GAPDH mRNA.
In situ hybridization
Mouse cDNAs for CRH (1–564 bp; full cording sequence),
Brn-2 (800–1335 bp in coding sequence), Arnt2 (1600–
2136 bp in coding sequence) and p39 (529–1110 bp in
coding sequence) were subcloned into pGEM-T-easy vector,
and used as a template for in vitro transcription of
digoxigenin-labeled riboprobes. We also used IMAGE
clones 640127 and 16180045, containing mouse cDNAs for
OT and VP, respectively, for probe synthesis as described pre-
viously (6). The probes were subjected to in situ hybridization
using 20 mm brain sections of mice ﬁxed with 4% paraformal-
dehyde/PBS by perfusion as described previously (6).
Protein puriﬁcation from E. coli
GST-Nhtt containing polyglutamine stretches of 18Q or 62Q
were puriﬁed from transformed E. coli (BL21) carrying
pGEX-6P-Nhtt 18Q or 62Q, respectively, as described pre-
viously (50). For puriﬁcation of His-TF-Brn-2, we incubated
transformed E. coli (BL21) carrying pCold-TF-Brn-2 grown
in LB medium with 0.1 mM isopropyl-beta-D-thiogalactopyra-
noside (IPTG) at 168C for overnights. The cells were sus-
pended with PBS containing complete protease inhibitor.
After addition of Triton-X 100 (ﬁnal conc.; 1%) and lysozyme
(ﬁnal conc.; 0.5 mg/ml), cells were sonicated and subjected to
centrifugation at 12 000 rpm for 30 min. The supernatants
were incubated with HIS-Select Nickel Afﬁnity Gel
(SIGMA) at 48C for 2 h. After washing the gel with buffer
A (50 mM Tris–HCl, pH 8.0,150 mM NaCl, 0.035%
b-mercaptoethanol, 10% glycerol) and 10 mM imidazole/
buffer A, the protein was eluted with 200 mM imidazole/
buffer A. The eluted proteins were dialyzed with buffer A
for 2 h at 48C using a Slide-A-Lyzer Cassette (PIERCE).
Filter trap assay
0.2 mg/ml of GST-Nhtt proteins or BSA in 25 ml of buffer A
was incubated with  1 ml of HRV-3C protease (Novagen) at
48C for 2 h to cut off Nhtt from GST. Different amounts of
2110 Human Molecular Genetics, 2010, Vol. 19, No. 11His-TF-Brn-2 (0, 0.2, 0.5 or 1 mg/ml) in 25 ml of buffer A
were also incubated with  1 ml of HRV-3C protease at 48C
for 2 h to cut off Brn-2 from His-TF. These proteins were
mixed and incubated at 378C for 20 h. After boiling in SDS
sample buffer, the samples were ﬁltered by cellulose acetate
membrane with 0.2 mm pore size (ADVANTEC), and
washed with buffer containing 2% SDS, 50 mM Tris–HCl,
pH8.0, 10% glycerol. After blocking the membrane with 5%
skim milk in TBST, trapped proteins were detected by incu-
bation with anti-huntingtin (EM48) or anti-Brn-2 (C-2AP),
followed by HRP-conjugated anti-mouse or rabbit IgG,
respectively.
Statistical analysis
All data were ﬁrst analyzed by F-test. For P . 0.05, the data
were analyzed by Student’s t-test; otherwise data were ana-
lyzed by Welch’s t-test. P , 0.05 by t-test was considered
statistically signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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